MedTrace Logo

β-hydroxy-β-methylbutyrate-enriched Nutritional Supplements for Obesity Adults

NCT04953936 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2021-09-14

No results posted yet for this study

Summary

The purpose of this study is to assess the effectiveness and safety of HMB-enriched nutritional supplements for improving muscle mass and muscle function in Chinese adults with obesity during the weight loss process using calorie restriction.

Conditions

Interventions

DIETARY_SUPPLEMENT

HMB-enriched Nutritional Supplements

The participants will receive oral HMB-enriched nutritional supplements (65 g, once daily), which include soybean isolate protein, flaxseed oil powder, yam powder, whey protein, oligomeric isomaltose powder, cocoa powder, medium-chain fatty acid powder, calcium beta-hydroxy-beta-methylbutyrate, sunflower seed oil powder, L-glutamine, wheat germ powder, membrane isolated casein, wheat oligopeptide, konjac flour, vitamin E, vitamin D, stevioside, edible flavors.

DIETARY_SUPPLEMENT

Placebo

Placebo (maltodextrin 65 g once daily) with the same package as the intervention.

BEHAVIORAL

Caloric Restrition Diet

Caloric restriction diet with individualized nutritional guidance from professional dietitians by video regarding caloric restriction strategies

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Principal Investigators

  • Ming Yang · West China Hospital

  • Jiaojiao Jiang · West China Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-20
Primary Completion
2021-10-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04953936 on ClinicalTrials.gov